Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data. PKU is a rare ...
A recently introduced bill would tighten health systems’ eligibility requirements to participate in the 340B Drug Pricing Program and increase transparency to show how savings are used.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback